JW Life Science Q1 2026 Preliminary: Operating Profit +33% QoQ, -14% YoY
-
Q1 2026 preliminary results (separate K-IFRS, unaudited)
-
Revenue: 59,263 million won (+2.09% QoQ, -4.48% YoY)
-
Operating profit: 8,918 million won (+32.99% QoQ, -14.01% YoY)
-
Net income: 6,224 million won (+14.86% QoQ, -12.39% YoY)
-
Improved from previous quarter but declined YoY
KOSPI Filing Information
-
Filing: Preliminary Operating Results (Fair Disclosure)
-
Company: JW LIFESCIENCE (234080)
-
Submission: JW LIFESCIENCE CORPORATION
-
Receipt: 05-13-2026
-
Under KRX KOSPI Market Division